Q32 Bio and Homology Medicines Announce Merger Agreement
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bios two clinical development candidates, bempikibart in Phase 2 for the treatment of atopic dermatitis and...
Source: marketscreener.com